Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 7/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | GPR6 | P46095 | 3/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240923 | 1.00 | GFER (0.40) | GFERAURKAHRH4GPR6RPS6KA2 | |
| SCHEMBL4249003 | 0.90 | GFER (0.42) | GFERAURKAHRH4GPR6THRB | |
| SCHEMBL4249000 | 0.90 | GFER (0.42) | GFERAURKAHRH4GPR6THRB | |
| SCHEMBL8224528 | 0.88 | HCRTR1 (0.46) | GFERHRH4RPS6KA2ALDH1A1HCRTR1 | |
| SCHEMBL1463387 | 0.87 | THRB (0.42) | HCRTR1HCRTR2THRBMAPK10 | |
| SCHEMBL1463384 | 0.87 | THRB (0.42) | HCRTR1HCRTR2THRBMAPK10 | |
| SCHEMBL1463388 | 0.87 | THRB (0.42) | HCRTR1HCRTR2THRBMAPK10 | |
| SCHEMBL4244415 | 0.83 | GFER (0.46) | GFERGPR6HCRTR1HCRTR2 | |
| SCHEMBL4244423 | 0.83 | GFER (0.46) | GFERGPR6HCRTR1HCRTR2 | |
| SCHEMBL8224518 | 0.80 | CYP2C9 (0.42) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | GFER 607/4885AURKA 3244/4885HRH4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.